

**MINUTE  
AREA DRUG AND THERAPEUTICS COMMITTEE  
WEDNESDAY 20<sup>th</sup> April 2022 @10am  
Microsoft Teams Meeting**

**In Attendance:**

|                     |                     |                       |
|---------------------|---------------------|-----------------------|
| Dr Mehrdad Malekian | Mrs Karen Patterson | Mrs Christine Gilmour |
| Mr George Lindsay   | Dr Stephanie Dundas | Mr John Milne         |
| Dr Iain Hathorn     | Mrs Carol McGoff    | Mrs Emma Harris       |
| Mrs Gail Richardson | Dr Tyra Smyth       | Mrs Penny Brankin     |
| Ms Ann Auld         |                     |                       |

|                   |   |           |
|-------------------|---|-----------|
| <b>2022/55 1.</b> | <b><u>Apologies for Absence</u></b><br><br>Mr Bill Angus, Dr David Semple, Mrs Katrina Maroni, Ms Linda Johnstone   |           |
| <b>2022/56 2.</b> | <b><u>Declaration of Interest</u></b><br><br>There were no declarations of interest.  |           |
| <b>2022/57 3.</b> | <b><u>Matters arising not covered elsewhere on the agenda</u></b><br><br><b>a. <u>Ratification of minutes of meeting 16<sup>th</sup> March 2022</u></b><br><br>The minutes were agreed subject to the following changes:<br><br>Item 2022/43 7a should read<br><br>There was useful discussion around the guidance for canagliflozin and heart failure and the difference between heart failure with preserved ejection fraction versus heart failure with reduced ejection fraction. The advice relating to SGLT2 inhibitors and “sick day rules” was also noted.<br><br>Item 22246 10 should read<br><br>Systems to assure timely review .....<br><br>The minute can be published once these changes are made.<br><br><b>b. <u>Steroid Emergency Cards</u></b><br><br>Mrs Gilmour will contact Helen Lindsay at ADTCC to clarify progress of the national project to identify patients who may benefit from these cards. Following that she will debate local systems with Mr Kenneth Mackenzie and Dr Burns. | <b>CG</b> |

|            |   |           |
|------------|---|-----------|
|            | <p><b>c. <u>Management of Cholesterol in Adults</u></b></p> <p>An updated version with minor typographical amendments has been received and has been agreed. Mr Lindsay will inform Mrs Milne.</p> <p><b>d. <u>A guideline for Periprocedure management of coagulation.</u></b></p> <p>An updated version is anticipated for the May meeting.</p> <p><b>e. <u>Scottish Medicines Consortium - Request for expressions of interest for Membership</u></b></p> <p>One member has expressed an interest and is arranging directly to observe an SMC/NDC meeting</p>  | <b>GL</b> |
| 2022/58 4. | <p><b><u>SMC PAPERS</u></b></p> <p><b><u>FULL SUBMISSIONS</u></b></p> <p><b>Ropeginterferon alfa-2b (Besremi®) SMC2421</b><br/>This was noted.</p> <p><b>Pembrolizumab (Keytruda®) Ltd SMC2420</b><br/>This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p><b>Daratumumab (Darzalex®) SMC2416</b><br/>This was noted.</p> <p><b>Dapagliflozin (Forxiga®) SMC2428</b><br/>This was noted and will be referred to the renal specialists.</p> <p><b><u>NON SUBMISSIONS</u></b></p> <p><b>Mepolizumab (Nucala®) SMC2488</b><br/>This was noted.</p> <p><b>Mepolizumab (Nucala®) SMC2490</b><br/>This was noted.</p> <p><b>Mepolizumab (Nucala®) SMC2491</b><br/>This was noted.</p> <p><b>Cemiplimab (Libtayo®) SMC2489</b><br/>This was noted.</p> |           |

|                       |  |      |
|-----------------------|--|------|
|                       | <p><b><u>UPDATE ON THE INTERIM ASSESSMENT APPROACH IN RESPONSE TO COVID-19</u></b></p> <p>This is a pragmatic approach to minimise delay in patient access as a result of the COVID-19 pandemic. Following review by the SMC executive, SMC advice for four submissions noted below will be published on the SMC website on <b>Monday 09 May 2022</b>.</p> <p><b><u>FULL SUBMISSIONS</u></b></p> <p><b>Venetoclax (Venclyxto®) SMC2427</b><br/>This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p><b>Nivolumab (Opdivo®) SMC2429</b><br/>This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p><b><u>RESUBMISSION</u></b></p> <p><b>Liraglutide (Saxenda®) SMC2455</b><br/>This was noted and will be referred to weight management colleagues for further advice.</p> <p><b><u>ABBREVIATED SUBMISSION</u></b></p> <p><b>Filgotinib (Jyseleca®) SMC2467</b><br/>This was noted and will be referred to the gastroenterology specialists.</p> <p><b><u>Deferred Advice</u></b></p> <p><b>Oritavancin (Tenkasi®) SMC2285</b><br/>This was noted and will be referred to the Antimicrobial Committee.</p> <p><b><u>PAEDIATRIC LICENCE EXTENSIONS</u></b><br/>These were noted.</p> |      |
| 2022/59 5.            | <p><b><u>SMC follow up</u></b></p> <p>Mrs McGoff talked the committee through the SMC follow up which had been previously circulated.<br/>Feedback for Risankizumab (Skyrizi®) SMC2459 was provided and the corresponding ADTC bulletin will be updated accordingly for this.</p>  | CMcG |
| 2022/60 6.<br><br>(a) | <p><b><u>Lanarkshire Formulary</u></b></p> <p><u>Formulary Amendments</u></p> <p>Mrs McGoff raised three formulary amendments.</p>   | CMcG |

|  |  |                                   |
|--|--|-----------------------------------|
|  | <p>The first was the proposed addition of cenobamate to the formulary, following SMC approval, in patients with drug-resistant epilepsy as a second-line adjunctive anti-seizure medicine, after the failure of the first adjunctive anti-seizure medicine. This has been discussed with neurology.</p> <p>The second was the amendment of the prescribing note for sevelamer. This now asks prescribers to prescribe generically, and an amendment to the restriction to remove 'receiving haemodialysis'.</p> <p>The third amendment is the removal of references to lofexidine in Chapter 4: Acute Opioid Withdrawal Symptoms. This is no longer available and it has been confirmed with the Substance Misuse Service that they do not use.</p> <p>The Committee had no further questions or comments.</p> <p><b>(b) <u>Gluten Free Formulary</u></b><br/> This has been reviewed and updated in conjunction with the Scottish Government Circular PCA (P)(2022) 05 and NHS Lanarkshire dietetics colleagues. This was ratified and will be circulated to community pharmacies in due course.</p>  |                                   |
| <p><b>2022/61 7.</b></p> <p><b>a.</b></p> <p><b>b.</b></p> | <p><b><u>Clinical Protocols</u></b></p> <p><b><u>Symptomatic Relief</u></b></p> <p>Mrs Brankin spoke to the paper and explained that there had been formatting issues but an update with format corrections will be shared.</p> <p>There was good discussion highlighting that the advance of HEPMA may mean that there is now only a niche place for SRP and that bespoke communications and related training may be required for those areas who will still use SRP.</p> <p>Mrs Brankin will circulate the reformatted version and all issues will be debated at the May meeting.</p> <p><b><u>Acute Deep Vein Thrombosis Catheter Directed Thrombolysis Protocol for Vascular Team. South West Scotland Vascular Network</u></b></p> <p>This is a complex document with many issues over and above the use of medicines. Some of the key issues relating to medicines include:</p> <ul style="list-style-type: none"> <li>• The unlicensed use of actilyse</li> <li>• The duration of actilyse in combination with anticoagulants and the associated monitoring</li> <li>• Assuring continuity of care across the interface of different teams within the hospital setting and general practice.</li> </ul> <p>Dr Malekian will feedback to the authors with a view to a presentation/discussion with an author at the May meeting.</p> | <p><b>PB</b></p> <p><b>MM</b></p> |

|         |  |      |
|---------|--|------|
|         |  |      |
| 2022/62 | 8. <b><u>ADTC New Medicines Decisions</u></b><br><br>This was noted.   | CMcG |
| 2022/63 | 9. <b><u>Unlicensed Medicines</u></b><br><br>There was nil to note at today's meeting.   |      |
| 2022/64 | 10. <b><u>Patient Group Directions</u></b><br><br>There was good debate and with the correction of some minor typographical errors this PGD was approved. Mr Lindsay will feedback to Sexual Health  | GL   |
| 2022/65 | 11. <b><u>Medication and Clinical risk in Lanarkshire</u></b><br><a href="https://www.gov.uk/drug-safety-update">https://www.gov.uk/drug-safety-update</a><br><br>This was noted and it was agreed that the risks of pregabalin use during pregnancy would be highlighted in Prescribing Notes   | EH   |
| 2022/66 | 12. <b><u>Regional Cancer Advisory Network</u></b><br><br>There was nil to note at today's meeting.  |      |
| 2022/67 | 13. <b><u>Patient Safety Alerts</u></b><br><br>There was nil to note at today's meeting.   |      |
| 2022/68 | 14. <b><u>Lay member related items</u></b><br><br>There was nil to note at today's meeting.  |      |
| 2022/69 | 15. <b><u>ADTCC Correspondence</u></b><br><br>a. <b><u>National Cancer Medicines Advisory Group (NCMAG) Programme</u></b><br><br>This was noted.<br><br>b. <b><u>Lutetium Vipicotide Tetrexetan Operational Guidance</u></b><br><br>This was noted.<br><br><b><u>NRP Membership</u></b><br><br>c. Mrs Gilmour will discuss with NHS Lanarkshire staff experienced in the PACS Tier 2 process to see if any will volunteer for this panel.<br><br>d. <b><u>Sapropterin</u></b><br><br>This was noted. | CG   |

|             |  |           |
|-------------|--|-----------|
| 2022/70 16. | <b>Pharmacy &amp; NMAHP Prescribing Governance</b><br>Mrs Brankin will share the most recent minute when it becomes available.                           |           |
| 2022/71 17. | <b><u>AOCB</u></b><br><b><u>Scottish Medicines Consortium: interim process survey</u></b><br>Mrs Gilmour agreed to respond on behalf of NHS Lanarkshire. | <b>CG</b> |
| 2022/72 18. | <b><u>Date of next meeting</u></b><br>Wednesday 18 <sup>th</sup> May 2022 10am @ Microsoft Teams   |           |